Page last updated: 2024-08-21

alpha-aminopyridine and Respiration Disorders

alpha-aminopyridine has been researched along with Respiration Disorders in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Calverley, PMA; Fabbri, LM; Martinez, FJ; Rabe, KF	1
Boswell-Smith, V; Page, CP	1

Reviews

1 review(s) available for alpha-aminopyridine and Respiration Disorders

Article	Year
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:9 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Respiration Disorders; Time Factors	2006

Trials

1 trial(s) available for alpha-aminopyridine and Respiration Disorders

Article	Year
Effect of roflumilast in patients with severe COPD and a history of hospitalisation. The European respiratory journal, 2017, Volume: 50, Issue:1 Topics: Aged; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Female; Forced Expiratory Volume; Hospitalization; Humans; Male; Middle Aged; Phenotype; Phosphodiesterase 4 Inhibitors; Prognosis; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Respiration Disorders; Treatment Outcome	2017

Article

Year

Effect of roflumilast in patients with severe COPD and a history of hospitalisation.

The European respiratory journal, 2017, Volume: 50, Issue:1

Topics: Aged; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Female; Forced Expiratory Volume; Hospitalization; Humans; Male; Middle Aged; Phenotype; Phosphodiesterase 4 Inhibitors; Prognosis; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Respiration Disorders; Treatment Outcome

2017